• Conavi filed a preliminary short-form prospectus for a public offering of common shares or pre-funded common share purchase warrants.
• Deal to be run on a commercially reasonable efforts agency basis led by Bloom Burton Securities, with final size, pricing, and security mix to be set at pricing.
• Net proceeds earmarked for a limited market release in the United States, working capital, and general corporate purposes.
• Closing targeted for about May 28, 2026, subject to customary conditions and required regulatory and TSX Venture Exchange approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conavi Medical Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110700PRIMZONEFULLFEED9717177) on May 11, 2026, and is solely responsible for the information contained therein.